| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8e071d18fea054bf8d1420d483e78ed1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9985529ee812119b76fd420587d90ff4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_01a96e8bbea00eeaa0b50c2a0c000dba |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0275
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-8509
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0008 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 |
| filingDate |
1996-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2001-12-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c3e5da1a252a412327f8026b16a42ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa14dc861bcb24740db0ed544f405b05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c1364b48caeb435356df23f39c47202
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89d731f54713def6da90aa2e88cc21a9 |
| publicationDate |
2001-12-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-6333447-B1 |
| titleOfInvention |
Transgenic model of heart failure |
| abstract |
The present invention relates to transgenic models of heart failure and, more particularly, to transgenic animals and methods for testing the usefulness of chemical compounds in treating or preventing heart failure. A transgenic mouse was developed wherein Gsalpha is selectively overexpressed approximately three-fold in the heart. Although steady state adenylyl cyclase activities are not altered, both the percent of agonist high affinity beta-adrenergic receptors as well as the rate of catalyst activation are increased. In addition, physiological and pathological studies revealed that chronically-facilitated sympathetic stimulation causes adverse cardiac effects. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009083865-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112841091-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2009018193-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7462643-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004077723-A1 |
| priorityDate |
1996-03-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |